Acumen pharmaceuticals to participate in the 7th annual evercore isi healthconx conference

Newton, mass., nov. 26, 2024 (globe newswire) -- acumen pharmaceuticals, inc. (nasdaq: abos), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of alzheimer's disease, announced today that management will participate in a fireside chat at the 7th annual evercore isi healthconx conference on tuesday, dec. 3, 2024, at 3:00 p.m. et.
ABOS Ratings Summary
ABOS Quant Ranking